Colorectal Cancer — Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
Citation(s)
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Colorectal Cancer as 3rd or Above Therapy